Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2003 1
2004 2
2005 1
2006 2
2007 1
2009 2
2010 1
2011 3
2012 5
2013 4
2014 5
2015 1
2016 1
2017 6
2018 6
2019 7
2020 3
2021 4
2022 2
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

54 results

Results by year

Filters applied: . Clear all
Page 1
Liver X receptors induce antiproliferative effects in basal-like breast cancer.
Haugen MH, von der Lippe Gythfeldt H, Egeland EV, Svartdal Normann L, Pandya AD, Vedin LL, Juell S, Tenstad E, Øy GF, Kristian A, Marangoni E, Sørlie T, Steffensen K, Maelandsmo GM, Engebraaten O. Haugen MH, et al. Among authors: engebraaten o. Mol Oncol. 2023 Oct;17(10):2041-2055. doi: 10.1002/1878-0261.13476. Epub 2023 Jun 30. Mol Oncol. 2023. PMID: 37341140 Free PMC article.
Corrigendum to "Cabazitaxel-loaded Poly(2-ethylbutyl cyanoacrylate) nanoparticles improve treatment efficacy in a patient derived breast cancer xenograft", [Journal of Control Release, 293 (2019) 183-192].
Fusser M, Øverbye A, Pandya AD, Mørch Ý, Borgos SE, Kildal W, Snipstad S, Sulheim E, Fleten KG, Askautrud HA, Engebraaten O, Flatmark K, Iversen TG, Sandvig K, Skotland T, Mælandsmo GM. Fusser M, et al. Among authors: engebraaten o. J Control Release. 2022 Sep;349:1. doi: 10.1016/j.jconrel.2022.06.040. Epub 2022 Jul 2. J Control Release. 2022. PMID: 35792388 Free article. No abstract available.
Protein Signature Predicts Response to Neoadjuvant Treatment With Chemotherapy and Bevacizumab in HER2-Negative Breast Cancers.
Haugen MH, Lingjærde OC, Hedenfalk I, Garred Ø, Borgen E, Loman N, Hatschek T, Børresen-Dale AL, Naume B, Mills GB, Mælandsmo GM, Engebraaten O. Haugen MH, et al. Among authors: engebraaten o. JCO Precis Oncol. 2021 Jan 28;5:PO.20.00086. doi: 10.1200/PO.20.00086. eCollection 2021. JCO Precis Oncol. 2021. PMID: 34036235 Free PMC article. Clinical Trial.
Detection of phenotype-specific therapeutic vulnerabilities in breast cells using a CRISPR loss-of-function screen.
Barkovskaya A, Goodwin CM, Seip K, Hilmarsdottir B, Pettersen S, Stalnecker C, Engebraaten O, Briem E, Der CJ, Moestue SA, Gudjonsson T, Maelandsmo GM, Prasmickaite L. Barkovskaya A, et al. Among authors: engebraaten o. Mol Oncol. 2021 Aug;15(8):2026-2045. doi: 10.1002/1878-0261.12951. Epub 2021 May 1. Mol Oncol. 2021. PMID: 33759347 Free PMC article.
Immune phenotype of tumor microenvironment predicts response to bevacizumab in neoadjuvant treatment of ER-positive breast cancer.
von der Lippe Gythfeldt H, Lien T, Tekpli X, Silwal-Pandit L, Borgen E, Garred Ø, Skjerven H, Schlichting E, Lundgren S, Wist E, Naume B, Kristensen V, Børresen-Dale AL, Lingjaerde OC, Engebraaten O. von der Lippe Gythfeldt H, et al. Among authors: engebraaten o. Int J Cancer. 2020 Nov 1;147(9):2515-2525. doi: 10.1002/ijc.33108. Epub 2020 Jun 18. Int J Cancer. 2020. PMID: 32488909 Free article. Clinical Trial.
54 results